Key result
Dalteparin increased mean coagulation time from 65.4 s at baseline to 332.2 s at /mL, indicating ROTEM detects its anticoagulant effects only at supratherapeutic levels.
Why the study?
Does the thrombelastograph ROTEM® accurately detect the anticoagulant activity of dalteparin at therapeutic and supratherapeutic plasma concentrations in vitro?
Does the thrombelastograph ROTEM® accurately detect the anticoagulant activity of dalteparin at therapeutic and supratherapeutic plasma concentrations in vitro?
The thrombelastograph ROTEM® can only detect the anticoagulant effects of dalteparin at supratherapeutic levels, limiting its utility for routine therapeutic monitoring.
Answers are grounded in this paper and cite their sources.
May limit ROTEM for therapeutic dalteparin monitoring in animals; leaves open in vivo validation before any clinical role.
The low molecular weight heparin (LMWH) dalteparin is used, for example, to prevent primary venous thromboembolism in patients undergoing surgery or in medically ill patients. The anticoagulant activity of dalteparin can be monitored by measuring anti-factor Xa levels and activated partial thromboplastin time (aPTT); however, aPTT is an unreliable parameter in this case. The aim of the present in vitro study was to evaluate the thrombelastograph ROTEM(®) (Tem International, Munich, Germany) with respect to determining the anticoagulant activity of dalteparin at therapeutic and supratherapeutic plasma concentrations. 2. The ROTEM(®) parameters, namely coagulation time (CT), clot formation time (CFT) and maximum clot firmness (MCF), were measured using the reagents EXTEM and INTEM (Pentapharm, Munich, Germany) at increasing concentrations of dalteparin (0.01-10 μg/mL, which corresponded to anti-factor Xa levels of 1-1000 U/mL, respectively). 3. The mean CT measured using EXTEM was found to increase from 65.4 ± 27.9 s at baseline to 173.3 ± 112.2 s and 332.2 ± 200.7 s at drug concentrations of 1 and 10 μg/mL, respectively (P < 0.0001 for both). Moreover, the mean CFT value (EXTEM) increased from 97.7 ± 21.5 s at baseline to 187.6 ± 115.2 s (P = 0.0001) at a drug concentration of 10 μg/mL, which is greater than the therapeutic anti-factor Xa concentrations for LMWH. The results obtained when INTEM was used as the reagent were similar to those obtained using EXTEM. 4. In conclusion, the results indicate that the thrombelastograph ROTEM(®) can detect the anticoagulant effects of dalteparin only at supratherapeutic levels of anti-factor Xa.
No takes yet. Share an insight, caveat, or question.
Feuring et al. (2011) studied this question. Dalteparin vs. baseline was evaluated on Coagulation time (CT) measured using EXTEM (p=<0.0001). Dalteparin increased mean coagulation time from 65.4 s at baseline to 332.2 s at /mL, indicating ROTEM detects its anticoagulant effects only at supratherapeutic levels.
Synapse has enriched 10 related papers. Consider them for comparative context: